Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumabopen access
- Authors
- Sang, Yun Beom; Lee, Chaeryoung; Kim, Seul-Gi; Lee, Boyoung; Kang, Beodeul; Kim, Chan; Chon, Hong Jae
- Issue Date
- Mar-2024
- Publisher
- MDPI
- Keywords
- coronavirus disease 2019; unresectable hepatocellular carcinoma; liver function; atezolizumab; bevacizumab
- Citation
- JOURNAL OF CLINICAL MEDICINE, v.13, no.5
- Journal Title
- JOURNAL OF CLINICAL MEDICINE
- Volume
- 13
- Number
- 5
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26260
- DOI
- 10.3390/jcm13051335
- ISSN
- 2077-0383
- Abstract
- (1) Background: The coronavirus disease 2019 (COVID-19) pandemic has proven challenging to the management of patients with cancer, particularly those receiving systemic therapy. This study aimed to evaluate the impact of COVID-19 on patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab. (2) Methods: Patients with unresectable HCC who started atezolizumab/bevacizumab treatment between June 2020 and December 2021 at a tertiary cancer center in Korea were included (n = 241) and classified according to their COVID-19 status and severity. (3) Results: Thirty-five (14.5%) patients with unresectable HCC were diagnosed with COVID-19 during atezolizumab/bevacizumab treatment; 26 (74.2%) and nine (25.7%) in the low- and high-severity groups, respectively. The high-severity group showed higher neutrophil-to-lymphocyte ratios and lactate dehydrogenase levels. Liver and kidney injuries were observed in 31.4% and 17.1% of total patients, respectively. Liver injury was more prominent in patients with pre-existing liver dysfunction at baseline, who were more prevalent in the high-severity group. Atezolizumab/bevacizumab treatment was delayed by a median of 0 (range, 0-21) day in the low-severity group and 12 (range, 0-35) days in the high-severity group. The high-severity group showed worse post-infection progression-free survival (1.1 vs. 4.8 months, p = 0.017) and overall survival (2.2 months vs. not reached, p = 0.004). (4) Conclusions: Patients with impaired liver function at baseline are more susceptible to high-severity COVID-19, which affects atezolizumab/bevacizumab treatment outcomes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26260)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.